Can-Fite BioPharma Ltd.
Clinical-stage biopharma developing oral small-molecule drugs targeting the A3AR.
CANF | TA
Overview
Corporate Details
- ISIN(s):
- IL0010944739 (+2 more)
- LEI:
- 549300ZLRH6GSBOHFZ59
- Country:
- Israel
- Address:
- PO BOX 7537, 4917000 PETACH-TIKVA
- Website:
- https://www.canfite.com/
- Sector:
- Manufacturing
Description
Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company with integrated drug discovery and development capabilities. The company specializes in creating orally bioavailable small-molecule drugs. Its proprietary platform technology is centered on the A3 adenosine receptor (A3AR), a therapeutic target highly expressed in cancer and inflammatory cells but minimally in normal cells. Can-Fite's compounds bind to A3AR to initiate anti-cancer and anti-inflammatory effects by modulating cellular signal transduction pathways. The company's advanced pipeline features proprietary drug candidates in Phase II and Phase III clinical development for treating oncology, inflammatory, liver, and metabolic diseases. A lead drug, Namodenoson, is in a pivotal Phase III study for advanced liver cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2024-07-03 22:14 |
Results of the Annual General Meeting of the Shareholders held on July 3, 2024
|
English | HTM • 36.7 KB | ||
| 2024-07-01 15:59 |
Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with N…
|
English | PDF • 140.8 KB | ||
| 2024-07-01 15:59 |
Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with N…
|
English | HTM • 36.5 KB | ||
| 2024-06-29 01:14 |
PROSPECTUS SUPPLEMENT NO. 1
(To Prospectus dated January 5, 2024)
|
English | PDF • 149.6 KB | ||
| 2024-06-29 01:14 |
PROSPECTUS SUPPLEMENT NO. 1
(To Prospectus dated January 5, 2024)
|
English | HTM • 36.5 KB | ||
| 2024-06-28 15:59 |
Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fi…
|
English | PDF • 162.4 KB | ||
| 2024-06-28 15:59 |
Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fi…
|
English | HTM • 36.6 KB | ||
| 2024-06-27 01:14 |
Annual General Meeting will be reconvened on Wednesday, July 3, 2024 at 3:00p.m…
|
English | PDF • 100.3 KB | ||
| 2024-06-27 01:14 |
Annual General Meeting will be reconvened on Wednesday, July 3, 2024 at 3:00p.m…
|
English | HTM • 37.0 KB | ||
| 2024-06-24 15:59 |
Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect…
|
English | PDF • 119.0 KB | ||
| 2024-06-24 15:59 |
Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect…
|
English | HTM • 36.6 KB | ||
| 2024-06-10 15:59 |
Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson i…
|
English | PDF • 174.2 KB | ||
| 2024-06-10 15:59 |
Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson i…
|
English | HTM • 36.5 KB | ||
| 2024-06-08 01:33 |
Immediate Report of Meeting to be held on June 26, 2024- proxy-amendment
|
English | PDF • 960.8 KB | ||
| 2024-06-08 01:33 |
Immediate Report of Meeting to be held on June 26, 2024- proxy-amendment
|
English | PDF • 960.8 KB |
Automate Your Workflow. Get a real-time feed of all Can-Fite BioPharma Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Can-Fite BioPharma Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Can-Fite BioPharma Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
